
Global Acute Ischemic Stroke Therapeutics Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Acute Ischemic Stroke Therapeutics market size will reach US$ million by 2031.
AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternative therapies, extensive use of generics, and unmet needs for anticoagulant reversal agents.
Technavio"s analysts forecast the global acute ischemic stroke therapeutics market to grow at a CAGR of 2.11% during the period 2017-2025.
LPI (LP Information)' newest research report, the “Acute Ischemic Stroke Therapeutics Industry Forecast” looks at past sales and reviews total world Acute Ischemic Stroke Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Acute Ischemic Stroke Therapeutics sales for 2025 through 2031. With Acute Ischemic Stroke Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Acute Ischemic Stroke Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Acute Ischemic Stroke Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Acute Ischemic Stroke Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Acute Ischemic Stroke Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Acute Ischemic Stroke Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Acute Ischemic Stroke Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Acute Ischemic Stroke Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Thrombolytic Therapeutics
Antihypertensive Therapeutics
Antiplatelet Therapeutics
Anticoagulants
Segmentation by Application:
Hospitals
Ambulatory Surgical Center
Diagnostic Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Boehringer Ingelheim
Roche
Sanofi
Biogen
Daiichi Sankyo
Pfizer
Please note: The report will take approximately 2 business days to prepare and deliver.
AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternative therapies, extensive use of generics, and unmet needs for anticoagulant reversal agents.
Technavio"s analysts forecast the global acute ischemic stroke therapeutics market to grow at a CAGR of 2.11% during the period 2017-2025.
LPI (LP Information)' newest research report, the “Acute Ischemic Stroke Therapeutics Industry Forecast” looks at past sales and reviews total world Acute Ischemic Stroke Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Acute Ischemic Stroke Therapeutics sales for 2025 through 2031. With Acute Ischemic Stroke Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Acute Ischemic Stroke Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Acute Ischemic Stroke Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Acute Ischemic Stroke Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Acute Ischemic Stroke Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Acute Ischemic Stroke Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Acute Ischemic Stroke Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Acute Ischemic Stroke Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Thrombolytic Therapeutics
Antihypertensive Therapeutics
Antiplatelet Therapeutics
Anticoagulants
Segmentation by Application:
Hospitals
Ambulatory Surgical Center
Diagnostic Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Boehringer Ingelheim
Roche
Sanofi
Biogen
Daiichi Sankyo
Pfizer
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
89 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Acute Ischemic Stroke Therapeutics Market Size by Player
- 4 Acute Ischemic Stroke Therapeutics by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Acute Ischemic Stroke Therapeutics Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.